The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

Pharmacological Research

Volumn 125, Issue , 2017, Pages 21-38

  Li, Xiao C ^a   Zhang, Jianfeng ^b   Zhuo, Jia L ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

ACE2; Alamandine; Angioprotectin; Angiotensin (1 7); Angiotensin 1 converting enzyme; Angiotensin II; Cardiovascular disease; Dipeptidyl peptidase III; Hypertension

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; COMPOUND 21; DIPEPTIDYL CARBOXYPEPTIDASE; GLUTAMYL AMINOPEPTIDASE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; RENIN; RESORCINOLNAPHTHALEIN; UNCLASSIFIED DRUG; XANTHENONE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTORADIOGRAPHY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DIURETIC ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EXPERIMENTAL PULMONARY HYPERTENSION; HEART PROTECTION; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MORPHOLOGY; NONHUMAN; OSMOLALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 85020762893     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.06.005     Document Type: Review

References (225)

1. de Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., Unger, T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52:3 (2000), 415–472.
2. Coffman, T.M., Under pressure: the search for the essential mechanisms of hypertension. Nat. Med. 17:11 (2011), 1402–1409.
3. Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59:3 (2007), 251–287.
4. Carey, R.M., Siragy, H.M., Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24 (2003), 261–271.
5. Zhuo, J.L., Ferrao, F.M., Zheng, Y., Li, X.C., New frontiers in the intrarenal Renin-Angiotensin system: a critical review of classical and new paradigms. Front. Endocrinol. (Lausanne), 4, 2013, 166, 10.3389/fendo.2013.00166.
6. Tigerstedt, R., Bergman, P.G., Niere und kreislauf. Scand. Arch. Physiol. 8 (1898), 223–271.
7. Goldblatt, H., Lynch, J., Hanzal, R.F., Summerville, W.W., Studies on experimental hypertension. 1. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J. Exp. Med. 59 (1934), 347–379.
8. Skeggs, L.T. Jr., Kahn, J.R., Lentz, K., Shumway, N.P., The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. 106:3 (1957), 439–453.
9. Tewksbury, D.A., Frome, W.L., Dumas, M.L., Characterization of human angiotensinogen. J. Biol. Chem. 253:11 (1978), 3817–3820.
10. Ohkubo, H., Kageyama, R., Ujihara, M., Hirose, T., Inayama, S., Nakanishi, S., Cloning and sequence analysis of cDNA for rat angiotensinogen. Proc. Natl. Acad. Sci. U. S. A. 80:8 (1983), 2196–2200.
11. Skeggs, L.T., Dorer, F.E., Kahn, J.R., Lentz, K.E., Levine, M., The biological production of angiotensin. Eichler, O., Farah, A., Herken, H., Welch, A.D., (eds.) Handbook of Experimental Pharmacology XXXVII: Angiotensin, 1974, Springer-Verlag, Berlin, Heidelberg, New York, 1–16.
12. Skeggs, L.T. Jr., Kahn, J.R., Shumway, N.P., The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103:3 (1956), 295–299.
13. Yang, H.Y., Erdos, E.G., Levin, Y., Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J. Pharmacol. Exp. Ther. 177:1 (1971), 291–300.
14. Carretero, O.A., Oza, N.B., Piwonska, A., Ocholik, T., Scicli, A.G., Measurement of urinary kallikrein activity by kinin radioimmunoassay. Biochem. Pharmacol. 25:20 (1976), 2265–2270.
15. Linz, W., Wiemer, G., Gohlke, P., Unger, T., Scholkens, B.A., Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47:1 (1995), 25–49.
16. Rhaleb, N.E., Yang, X.P., Carretero, O.A., The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr. Physiol. 1:2 (2011), 971–993.
17. Ardaillou, R., Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr. Opin. Nephrol. Hypertens. 6:1 (1997), 28–34.
18. Kemp, B.A., Bell, J.F., Rottkamp, D.M., Howell, N.L., Shao, W., Navar, L.G., Padia, S.H., Carey, R.M., Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 60 (2012), 387–395.
19. Padia, S.H., Kemp, B.A., Howell, N.L., Siragy, H.M., Fournie-Zaluski, M.C., Roques, B.P., Carey, R.M., Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 49:3 (2007), 625–630.
20. Healy, D.P., Song, L., Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. Hypertension 33:2 (1999), 740–745.
21. Khosla, M.C., Smeby, R.R., Bumpus, F.M., Structure-activity relationship in angiotensin analogs. Page, I.H., Bumpus, F.M., (eds.) Handbook of Experimental Pharmacology XXXVII: Angiotensin, 1974, Springer-Verlag, Berlin, Heidelberg, New York, 126–161.
22. Fitzgerald, S.M., Evans, R.G., Bergstrom, G., Anderson, W.P., Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats. J. Cardiovasc. Pharmacol. 34:2 (1999), 206–211.
23. 1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Am. J. Physiol. Renal Physiol. 290:5 (2006), F1024–F1033.
24. 2 receptor activation induces natriuresis and lowers blood pressure. Circ. Res. 115:3 (2014), 388–399.
25. 2 receptors. Curr. Opin. Nephrol. Hypertens. 26:2 (2017), 91–96.
26. 4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276:52 (2001), 48623–48626.
27. 4 receptors. J. Hypertens. 16:12 Pt. 2 (1998), 2027–2037.
28. 4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J. Neurochem. 86:2 (2003), 344–350.
29. Timmermans, P.B., Smith, R.D., Angiotensin II receptors and functional correlates. Am. J. Hypertens. 5:12 Pt. 2 (1992), 221S–235S.
30. Timmermans, P.B., Wong, P.C., Chiu, A.T., Herblin, W.F., Benfield, P., Carini, D.J., Lee, R.J., Wexler, R.R., Saye, J.A., Smith, R.D., Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45:2 (1993), 205–251.
31. Karnik, S.S., Unal, H., Kemp, J.R., Tirupula, K.C., Eguchi, S., Vanderheyden, P.M., Thomas, W.G., International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]. Pharmacol. Rev. 67:4 (2015), 754–819.
32. Murphy, T.J., Alexander, R.W., Griendling, K.K., Runge, M.S., Bernstein, K.E., Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 16:351 (1991), 233–236.
33. Sasaki, K., Yamano, Y., Bardhan, S., Iwai, N., Murray, J.J., Hasegawa, M., Matsuda, Y., Inagami, T., Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351:6323 (1991), 230–233.
34. Mukoyama, M., Nakajima, M., Horiuchi, M., Sasamura, H., Pratt, R.E., Dzau, V.J., Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268:33 (1993), 24539–24542.
35. Nakajima, M., Mukoyama, M., Pratt, R.E., Horiuchi, M., Dzau, V.J., Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 197:2 (1993), 393–399.
36. Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, T., Inagami, T., Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 268:33 (1993), 24543–24546.
37. Sandberg, K., Ji, H., Clark, A.J., Shapira, H., Catt, K.J., Cloning and expression of a novel angiotensin II receptor subtype. J. Biol. Chem. 267:14 (1992), 9455–9458.
38. 4 receptor. Cell. Mol. Life Sci. 61:21 (2004), 2728–2737.
39. Santos, R.A., Simoes e Silva, A.C., Maric, C., Silva, D.M., Machado, R.P., de, B. I, Heringer-Walther, S., Pinheiro, S.V., Lopes, M.T., Bader, M., Mendes, E.P., Lemos, V.S., Campagnole-Santos, M.J., Schultheiss, H.P., Speth, R., Walther, T., Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100:14 (2003), 8258–8263.
40. Bader, M., Alenina, N., Andrade-Navarro, M.A., Santos, R.A., MAS and its related G protein-coupled receptors, Mrgprs. Pharmacol. Rev. 66:4 (2014), 1080–1105.
41. Chappell, M.C., Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 50:4 (2007), 596–599.
42. Ferrario, C.M., Angiotensin-converting enzyme 2 and angiotensin-(1–7): an evolving story in cardiovascular regulation. Hypertension 47:3 (2006), 515–521.
43. Solinski, H.J., Gudermann, T., Breit, A., Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol. Rev. 66:3 (2014), 570–597.
44. Nguyen, G., The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr. Opin. Nephrol. Hypertens. 16:2 (2007), 129–133.
45. 2) angiotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 96:11 (1999), 6506–6510.
46. Pang, X., Shimizu, A., Kurita, S., Zankov, D.P., Takeuchi, K., Yasuda-Yamahara, M., Kume, S., Ishida, T., Ogita, H., Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertension 68:3 (2016), 630–641.
47. Villela, D.C., Passos-Silva, D.G., Santos, R.A., Alamandine: a new member of the angiotensin family. Curr. Opin. Nephrol. Hypertens. 23:2 (2014), 130–134.
48. Lautner, R.Q., Villela, D.C., Fraga-Silva, R.A., Silva, N., Verano-Braga, T., Costa-Fraga, F., Jankowski, J., Jankowski, V., Sousa, F., Alzamora, A., Soares, E., Barbosa, C., Kjeldsen, F., Oliveira, A., Braga, J., Savergnini, S., Maia, G., Peluso, A.B., Passos-Silva, D., Ferreira, A., Alves, F., Martins, A., Raizada, M., Paula, R., Motta-Santos, D., Klempin, F., Pimenta, A., Alenina, N., Sinisterra, R., Bader, M., Campagnole-Santos, M.J., Santos, R.A., Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ. Res. 112:8 (2013), 1104–1111.
49. Qaradakhi, T., Apostolopoulos, V., Zulli, A., Angiotensin (1–7) and alamandine: similarities and differences. Pharmacol. Res. 111 (2016), 820–826.
50. Jankowski, V., Tolle, M., Santos, R.A., Gunthner, T., Krause, E., Beyermann, M., Welker, P., Bader, M., Pinheiro, S.V., Sampaio, W.O., Lautner, R., Kretschmer, A., van der Giet, M., Zidek, W., Jankowski, J., Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J. 25:9 (2011), 2987–2995.
51. 1 receptor signaling cascades in cardiovascular physiopathology. Cell. Signal. 26:10 (2014), 2147–2160.
52. Guan, S., Fox, J., Mitchell, K.D., Navar, L.G., Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one-clip hypertensive rats. Hypertension 20 (1992), 763–767.
53. Navar, L.G., Kobori, H., Prieto, M.C., Gonzalez-Villalobos, R.A., Intratubular renin-angiotensin system in hypertension. Hypertension 57:3 (2011), 355–362.
54. Navar, L.G., Zou, L., Von Thun, A., Tarng, W.C., Imig, J.D., Mitchell, K.D., Unraveling the mystery of Goldblatt hypertension. News Physiol. Sci. 13 (1998), 170–176.
55. von Thun, A.M., Vari, R.C., El Dahr, S.S., Navar, L.G., Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am. J. Physiol. 266:1 Pt. 2 (1994), F120–F128.
56. Zou, L.X., Hymel, A., Imig, J.D., Navar, L.G., Renal accumulation of circulating angiotensin II in angiotensin II- infused rats. Hypertension 27:3 Pt. 2 (1996), 658–662.
57. 1 receptor. Hypertension 39:1 (2002), 116–121.
58. Esther, C.R., Marino, E.M., Howard, T.E., Machaud, A., Corvol, P., Capecchi, M.R., Bernstein, K.E., The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest. 99 (1997), 2375–2385.
59. Gonzalez-Villalobos, R.A., Billet, S., Kim, C., Satou, R., Fuchs, S., Bernstein, K.E., Navar, L.G., Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin I infusion. J. Am. Soc. Nephrol. 22:3 (2011), 449–459.
60. Bernstein, K.E., Two ACEs and a heart. Nature 417:6891 (2002), 799–802.
61. Song, L., Healy, D.P., Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. Hypertension 33:2 (1999), 746–752.
62. Ahmad, S., Ward, P.E., Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J. Pharmacol. Exp. Ther. 252:2 (1990), 643–650.
63. Mentzel, S., Dijkman, H.B., Van Son, J.P., Koene, R.A., Assmann, K.J., Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J. Histochem. Cytochem. 44:5 (1996), 445–461.
64. Healy, D.P., Wilk, S., Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res. 606:2 (1993), 295–303.
65. Zini, S., Masdehors, P., Lenkei, Z., Fournie-Zaluski, M.C., Roques, B.P., Corvol, P., Llorens-Cortes, C., Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience 78:4 (1997), 1187–1193.
66. Lin, Q., Taniuchi, I., Kitamura, D., Wang, J., Kearney, J.F., Watanabe, T., Cooper, M.D., T and B cell development in BP-1/6C3/aminopeptidase A-deficient mice. J. Immunol. 160:10 (1998), 4681–4687.
67. Mitsui, T., Nomura, S., Okada, M., Ohno, Y., Kobayashi, H., Nakashima, Y., Murata, Y., Takeuchi, M., Kuno, N., Nagasaka, T., Wang, J., Cooper, M.D., Mizutani, S., Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mol. Med. 9:1–2 (2003), 57–62.
68. Faber, F., Gembardt, F., Sun, X., Mizutani, S., Siems, W.E., Walther, T., Lack of angiotensin II conversion to angiotensin III increases water but not alcohol consumption in aminopeptidase A-deficient mice. Regul. Pept. 136:1–3 (2006), 130–137.
69. Kubota, R., Numaguchi, Y., Ishii, M., Niwa, M., Okumura, K., Naruse, K., Murohara, T., Ischemia-induced angiogenesis is impaired in aminopeptidase A deficient mice via down-regulation of HIF-1alpha. Biochem. Biophys. Res. Commun. 402:2 (2010), 396–401.
70. Wolf, G., Assmann, K.J., Stahl, R.A., Overexpression of aminopeptidase A abolishes the growth promoting effects of angiotensin II in cultured mouse mesangial cells. Kidney Int. 52:5 (1997), 1250–1260.
71. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T. Jr., Roccella, E.J., Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:6 (2003), 1206–1252.
72. Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., Konstam, M.A., Riegger, G., Klinger, G.H., Neaton, J., Sharma, D., Thiyagarajan, B., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:9215 (2000), 1582–1587.
73. Zhuo, J.L., Froomes, P., Casley, D., Liu, J.J., Murone, C., Chai, S.Y., Buxton, B., Mendelsohn, F.A., Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 96:1 (1997), 174–182.
74. O'Brien, E., Barton, J., Nussberger, J., Mulcahy, D., Jensen, C., Dicker, P., Stanton, A., Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49:2 (2007), 276–284.
75. Ledingham, J.G., Leary, W.P., Catabolism of Angiotensin II. Handbook of Experimental Pharmacology XXXVII. 1974, Springer-Verlag, Berlin-Heidelberg-New York, 111–125.
76. Harris, P.J., Zhuo, J.L., Skinner, S.L., Effects of angiotensins II and III on glomerulotubular balance in rats. Clin. Exp. Pharmacol. Physiol. 14:6 (1987), 489–502.
77. i along the rat nephron. Kidney Int. 56:3 (1999), 850–859.
78. Campbell, D.J., Kladis, A., Simultaneous radioimmunoassay of six angiotensin peptides in arterial and venous plasma of man. J. Hypertens. 8 (1990), 165–172.
79. Campbell, D.J., Lawrence, A.C., Towrie, A., Kladis, A., Valentijn, A.J., Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:6 (1991), 763–773.
80. Chappell, M.C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?. Am. J. Physiol. Heart Circ. Physiol. 310:2 (2016), H137–H152.
81. Wysocki, J., Ye, M., Batlle, D., Plasma and kidney angiotensin peptides: importance of the aminopeptidase A/angiotensin III axis. Am. J. Hypertens. 28:12 (2015), 1418–1426.
82. Olkowicz, M., Radulska, A., Suraj, J., Kij, A., Walczak, M., Chlopicki, S., Smolenski, R.T., Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice. J. Chromatogr. A 1393 (2015), 37–46.
83. Seikaly, M.G., Arant, B.S. Jr., Seney, F.D. Jr., Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J. Clin. Invest. 86:4 (1990), 1352–1357.
84. 1 angiotensin II receptors in rat kidney. Ren. Physiol. Biochem. 15:5 (1992), 231–239.
85. Chappell, M.C., Nonclassical renin-angiotensin system and renal function. Compr. Physiol. 2:4 (2012), 2733–2752.
86. Yugandhar, V.G., Clark, M.A., Angiotensin III. A physiological relevant peptide of the renin angiotensin system. Peptides 46 (2013), 26–32.
87. 1)-angiotensin II and angiotensin II in man:Differences in blood pressure and adrenocortical response during normal and low sodium intake. J. Clin. Invest. 61:1 (1978), 20–31.
88. Gardiner, S.M., Kemp, P.A., March, J.E., Bennett, T., Regional haemodynamic effects of angiotensin II (3–8) in conscious rats. Br. J. Pharmacol. 110:1 (1993), 159–162.
89. Padia, S.H., Howell, N.L., Siragy, H.M., Carey, R.M., Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 47:3 (2006), 537–544.
90. Padia, S.H., Kemp, B.A., Howell, N.L., Gildea, J.J., Keller, S.R., Carey, R.M., Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension 53:2 (2009), 338–343.
91. Ichiki, T., Labosky, P.A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B.L., Inagami, T., Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:6551 (1995), 748–750.
92. 1 receptor blockade in conscious SHR. Br. J. Pharmacol. 142 (2004), 821–830.
93. 2 receptor agonists: hypertension and beyond. Curr. Opin. Nephrol. Hypertens. 21:2 (2012), 142–146.
94. 2 receptors: potential therapeutic targets for yypertension. Am. J. Hypertens. 30:4 (2017), 339–347.
95. 2 production in conscious rats. J. Clin. Invest. 97:8 (1996), 1978–1982.
96. 2 receptor in blood pressure regulation and therapeutic implications. Am. J. Hypertens. 14:6 Pt. 2 (2001), 98S–102S.
97. Siragy, H.M., Carey, R.M., Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr. Opin. Nephrol. Hypertens. 10:1 (2001), 99–103.
98. Zhuo, J.L., Alcorn, D., Harris, P.J., Mendelsohn, F.A., Localization and properties of angiotensin II receptors in rat kidney. Kidney Int. Suppl. 42 (1993), S40–S46.
99. Zhuo, J.L., Allen, A.M., Alcorn, D., MacGregor, D., Aldred, G.P., Mendelsohn, F.A., The distribution of angiotensin II receptors. Laragh, J.H., Brenner, B.M., (eds.) Hypertension: Pathology, Diagnosis & Management, 2nd edition, 1995, Raven Press, New York, 1739–1762.
100. 2 receptor binding sites in the adventitia of human kidney vasculature. Clin. Exp. Pharmacol. Physiol. Suppl. 3 (1996), S147–S154.
101. Zhuo, J.L., Yamada, H., Allen, A.M., Sun, Y., Mendelsohn, F.A., Localization and properties of angiotensin converting enzyme and angiotensin II receptors in the heart. Lindpaintner, K., Ganten, D., (eds.) The Cardiac Renin-Angiotensin System, 1994, Futura Scientific Publishing, New York, 63–88.
102. 2 receptors. J. Am. Soc. Nephrol. 10:Suppl. 11 (1999), S23–S29.
103. Tsuzuki, S., Ichiki, T., Nakakubo, H., Kitami, Y., Guo, D.F., Shirai, H., Inagami, T., Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 200:3 (1994), 1449–1454.
104. 1 receptor antagonist in hypertensive rats. Hypertension 34:5 (1999), 1112–1116.
105. Levy, B.I., Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109:1 (2004), 8–13.
106. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography. Clin. Exp. Pharmacol. Physiol. 21:7 (1994), 557–567.
107. Zhuo, J.L., Alcorn, D., McCausland, J., Casley, D., Mendelsohn, F.A., In vivo occupancy of angiotensin II subtype 1 receptors in rat renal medullary interstitial cells. Hypertension 23:6 Pt. 2 (1994), 838–843.
108. Hein, L., Barsh, G.S., Pratt, R.E., Dzau, V.J., Kobilka, B.K., Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377:6551 (1995), 744–747.
109. Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., Miwa, T., Kawada, N., Mori, Y., Shibasaki, Y., Tanaka, Y., Fujiyama, S., Koyama, Y., Fujiyama, A., Takahashi, H., Iwasaka, T., Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 104:7 (1999), 925–935.
110. Niimura, F., Labosky, P.A., Kakuchi, J., Okubo, S., Yoshida, H., Oikawa, T., Ichiki, T., Naftilan, A.J., Fogo, A., Inagami, T., Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J. Clin. Invest. 96:6 (1995), 2947–2954.
111. Kim, H.S., Krege, J.H., Kluckman, K.D., Hagaman, J.R., Hodgin, J.B., Best, C.F., Jennette, J.C., Coffman, T.M., Maeda, N., Smithies, O., Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. U. S. A. 92:7 (1995), 2735–2739.
112. Krege, J.H., John, S.W., Langenbach, L.L., Hodgin, J.B., Hagaman, J.R., Bachman, E.S., Jennette, J.C., O'Brien, D.A., Smithies, O., Male-female differences in fertility and blood pressure in ACE- deficient mice. Nature 375:6527 (1995), 146–148.
113. Tsuchida, S., Matsusaka, T., Chen, X., Okubo, S., Niimura, F., Nishimura, H., Fogo, A., Utsunomiya, H., Inagami, T., Ichikawa, I., Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J. Clin. Invest. 101:4 (1998), 755–760.
114. Oliverio, M.I., Kim, H.S., Ito, M., Le, T., Audoly, L., Best, C.F., Hiller, S., Kluckman, K., Maeda, N., Smithies, O., Coffman, T.M., Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc. Natl. Acad. Sci. U. S. A. 95:26 (1998), 15496–15501.
115. James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., Lackland, D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., Smith, S.C. Jr., Svetkey, L.P., Taler, S.J., Townsend, R.R., Wright, J.T. Jr., Narva, A.S., Ortiz, E., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:5 (2014), 507–520.
116. Casas, J.P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A.D., MacAllister, R.J., Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:9502 (2005), 2026–2033.
117. Wing, L.M., Reid, C.M., Ryan, P., Beilin, L.J., Brown, M.A., Jennings, G.L., Johnston, C.I., McNeil, J.J., Macdonald, G.J., Marley, J.E., Morgan, T.O., West, M.J., A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348:7 (2003), 583–592.
118. Yamada, T., Horiuchi, M., Dzau, V.J., Angiotensin II type 2 receptor mediates programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 93:1 (1996), 156–160.
119. Senbonmatsu, T., Ichihara, S., Price, E. Jr., Gaffney, F.A., Inagami, T., Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J. Clin. Invest. 106:3 (2000), R25–R29.
120. Ichihara, S., Senbonmatsu, T., Price, E. Jr., Ichiki, T., Gaffney, F.A., Inagami, T., Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104:3 (2001), 346–351.
121. Cao, Z., Kelly, D.J., Cox, A., Casley, D., Forbes, J.M., Martinello, P., Dean, R., Gilbert, R.E., Cooper, M.E., Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 58:6 (2000), 2437–2451.
122. Balla, T., Baukal, A.J., Eng, S., Catt, K.J., Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol. Pharmacol. 40:3 (1991), 401–406.
123. Goldfarb, D.A., Diz, D.I., Tubbs, R.R., Ferrario, C.M., Novick, A.C., Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J. Urol. 151:1 (1994), 208–213.
124. 1 receptor function and blood pressure in obese Zucker rats. Kidney Int. 84:5 (2013), 931–939.
125. Hakam, A.C., Hussain, T., Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats. Hypertension 47:6 (2006), 1117–1124.
126. 2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am. J. Physiol. Renal Physiol. 300:3 (2011), F700–F706.
127. Benndorf, R., Boger, R.H., Ergun, S., Steenpass, A., Wieland, T., Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ. Res. 93:5 (2003), 438–447.
128. 2 receptor agonist. J. Med. Chem. 47:24 (2004), 5995–6008.
129. 2 receptor research and therapeutic potential. J. Renin Angiotensin Aldosterone Syst. 11:1 (2010), 75–77.
130. Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Stroder, K., Thone-Reineke, C., Reichenbach, A., Schacherl, J., Dahlof, B., Bader, M., Alenina, N., Schwaninger, M., Zuberbier, T., Funke-Kaiser, H., Schmidt, C., Schunck, W.H., Unger, T., Steckelings, U.M., Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55:4 (2010), 924–931.
131. 2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 57:2 (2011), 308–313.
132. Matavelli, L.C., Zatz, R., Siragy, H.M., A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes. J. Cardiovasc. Pharmacol. 65:4 (2015), 371–376.
133. 2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. Br. J. Pharmacol. 173:4 (2016), 729–740.
134. Iwanami, J., Mogi, M., Tsukuda, K., Wang, X.L., Nakaoka, H., Kan-no, H., Chisaka, T., Bai, H.Y., Shan, B.S., Kukida, M., Horiuchi, M., Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia. J. Am. Soc. Hypertens. 9:4 (2015), 250–256.
135. Patel, S.N., Ali, Q., Hussain, T., Angiotensin II type 2-receptor agonist C21 reduces proteinuria and oxidative stress in kidney of high-salt-fed obese Zucker rats. Hypertension 67:5 (2016), 906–915.
136. 2 receptor agonist C21 on blood pressure and beyond. Curr. Hypertens. Rep. 14:5 (2012), 403–409.
137. Rehman, A., Leibowitz, A., Yamamoto, N., Rautureau, Y., Paradis, P., Schiffrin, E.L., Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59:2 (2012), 291–299.
138. Brouwers, S., Smolders, I., Massie, A., Dupont, A.G., Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo. Hypertension 62:5 (2013), 920–926.
139. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., Breitbart, R.E., Acton, S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res. 87:5 (2000), E1–E9.
140. Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G., Turner, A.J., A human homolog of angiotensin-converting enzyme:Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275:43 (2000), 33238–33243.
141. Marian, A.J., The discovery of the ACE2 gene. Circ. Res. 112:10 (2013), 1307–1309.
142. Danilczyk, U., Penninger, J.M., Angiotensin-converting enzyme II in the heart and the kidney. Circ. Res. 98:4 (2006), 463–471.
143. Ye, M., Wysocki, J., William, J., Soler, M.J., Cokic, I., Batlle, D., Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17:11 (2006), 3067–3075.
144. Tikellis, C., Johnston, C.I., Forbes, J.M., Burns, W.C., Burrell, L.M., Risvanis, J., Cooper, M.E., Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41:3 (2003), 392–397.
145. Lely, A.T., Hamming, I., van, G.H., Navis, G.J., Renal ACE2 expression in human kidney disease. J. Pathol. 204:5 (2004), 587–593.
146. Velez, J.C., Bland, A.M., Arthur, J.M., Raymond, J.R., Janech, M.G., Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am. J. Physiol. Renal Physiol. 293:1 (2007), F398–F407.
147. Reich, H.N., Oudit, G.Y., Penninger, J.M., Scholey, J.W., Herzenberg, A.M., Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 74:12 (2008), 1610–1616.
148. Mizuiri, S., Hemmi, H., Arita, M., Ohashi, Y., Tanaka, Y., Miyagi, M., Sakai, K., Ishikawa, Y., Shibuya, K., Hase, H., Aikawa, A., Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 51:4 (2008), 613–623.
149. Doobay, M.F., Talman, L.S., Obr, T.D., Tian, X., Davisson, R.L., Lazartigues, E., Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:1 (2007), R373–R381.
150. Crackower, M.A., Sarao, R., Oudit, G.Y., Yagil, C., Kozieradzki, I., Scanga, S.E., Oliveira-dos-Santos, A.J., da, C.J., Zhang, L., Pei, Y., Scholey, J., Ferrario, C.M., Manoukian, A.S., Chappell, M.C., Backx, P.H., Yagil, Y., Penninger, J.M., Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:6891 (2002), 822–828.
151. Gurley, S.B., Allred, A., Le, T.H., Griffiths, R., Mao, L., Philip, N., Haystead, T.A., Donoghue, M., Breitbart, R.E., Acton, S.L., Rockman, H.A., Coffman, T.M., Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116:8 (2006), 2218–2225.
152. Yamamoto, K., Ohishi, M., Katsuya, T., Ito, N., Ikushima, M., Kaibe, M., Tatara, Y., Shiota, A., Sugano, S., Takeda, S., Rakugi, H., Ogihara, T., Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47:4 (2006), 718–726.
153. Ferrario, C.M., Varagic, J., The ANG-(1–7)/ACE2/mas axis in the regulation of nephron function. Am. J. Physiol. Renal Physiol. 298:6 (2010), F1297–F1305.
154. Feng, Y., Yue, X., Xia, H., Bindom, S.M., Hickman, P.J., Filipeanu, C.M., Wu, G., Lazartigues, E., Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ. Res. 102:6 (2008), 729–736.
155. Feng, Y., Xia, H., Cai, Y., Halabi, C.M., Becker, L.K., Santos, R.A., Speth, R.C., Sigmund, C.D., Lazartigues, E., Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ. Res. 106:2 (2010), 373–382.
156. Wysocki, J., Ye, M., Rodriguez, E., Gonzalez-Pacheco, F.R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K.B., Ferrario, C.M., Penninger, J.M., Batlle, D., Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55:1 (2010), 90–98.
157. Nadarajah, R., Milagres, R., Dilauro, M., Gutsol, A., Xiao, F., Zimpelmann, J., Kennedy, C., Wysocki, J., Batlle, D., Burns, K.D., Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int. 82:3 (2012), 292–303.
158. Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., Krahenbuhl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52:9 (2013), 783–792.
159. Hernandez Prada, J.A., Ferreira, A.J., Katovich, M.J., Shenoy, V., Qi, Y., Santos, R.A., Castellano, R.K., Lampkins, A.J., Gubala, V., Ostrov, D.A., Raizada, M.K., Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51:5 (2008), 1312–1317.
160. Qi, Y., Zhang, J., Cole-Jeffrey, C.T., Shenoy, V., Espejo, A., Hanna, M., Song, C., Pepine, C.J., Katovich, M.J., Raizada, M.K., Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 62:4 (2013), 746–752.
161. Velkoska, E., Patel, S.K., Burrell, L.M., Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr. Opin. Nephrol. Hypertens. 25:5 (2016), 384–395.
162. Mecca, A.P., Regenhardt, R.W., O'Connor, T.E., Joseph, J.P., Raizada, M.K., Katovich, M.J., Sumners, C., Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 96:10 (2011), 1084–1096.
163. Rigatto, K., Casali, K.R., Shenoy, V., Katovich, M.J., Raizada, M.K., Diminazene aceturate improves autonomic modulation in pulmonary hypertension. Eur. J. Pharmacol. 713:1–3 (2013), 89–93.
164. Peregrine, A.S., Mamman, M., Pharmacology of diminazene: a review. Acta Trop. 54:3–4 (1993), 185–203.
165. Shenoy, V., Gjymishka, A., Jarajapu, Y.P., Qi, Y., Afzal, A., Rigatto, K., Ferreira, A.J., Fraga-Silva, R.A., Kearns, P., Douglas, J.Y., Agarwal, D., Mubarak, K.K., Bradford, C., Kennedy, W.R., Jun, J.Y., Rathinasabapathy, A., Bruce, E., Gupta, D., Cardounel, A.J., Mocco, J., Patel, J.M., Francis, J., Grant, M.B., Katovich, M.J., Raizada, M.K., Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 187:6 (2013), 648–657.
166. Young, D., Waitches, G., Birchmeier, C., Fasano, O., Wigler, M., Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45:5 (1986), 711–719.
167. Jackson, T.R., Blair, L.A., Marshall, J., Goedert, M., Hanley, M.R., The mas oncogene encodes an angiotensin receptor. Nature 335:6189 (1988), 437–440.
168. i responses in cells with pre-existing angiotensin II receptors. Biochim. Biophys. Acta 1133:1 (1991), 107–111.
169. Monnot, C., Weber, V., Stinnakre, J., Bihoreau, C., Teutsch, B., Corvol, P., Clauser, E., Cloning and functional characterization of a novel mas-related gene, modulating intracellular angiotensin II actions. Mol. Endocrinol. 5:10 (1991), 1477–1487.
170. Walther, T., Balschun, D., Voigt, J.P., Fink, H., Zuschratter, W., Birchmeier, C., Ganten, D., Bader, M., Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273:19 (1998), 11867–11873.
171. 2 receptor. Regul. Pept. 120:1–3 (2004), 167–175.
172. Walters, P.E., Gaspari, T.A., Widdop, R.E., Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45:5 (2005), 960–966.
173. Tetzner, A., Gebolys, K., Meinert, C., Klein, S., Uhlich, A., Trebicka, J., Villacanas, O., Walther, T., G-protein-coupled receptor MrgD is a receptor for angiotensin-(1–7) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension 68:1 (2016), 185–194.
174. Young, D., O'Neill, K., Jessell, T., Wigler, M., Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proc. Natl. Acad. Sci. U. S. A. 85:14 (1988), 5339–5342.
175. Gwathmey, T.M., Westwood, B.M., Pirro, N.T., Tang, L., Rose, J.C., Diz, D.I., Chappell, M.C., Nuclear angiotensin-(1–7) receptor is functionally coupled to the formation of nitric oxide. Am. J. Physiol. Renal Physiol. 299:5 (2010), F983–F990.
176. Su, Y., Bi, J., Pulgar, V.M., Chappell, M.C., Rose, J.C., Antenatal betamethasone attenuates the angiotensin-(1–7)/mas receptor/nitric oxide axis in isolated proximal tubule cells. Am. J. Physiol. Renal Physiol. 312:6 (2017), F1056–F1062, 10.1152/ajprenal.00593.2016.
177. Walther, T., Wessel, N., Kang, N., Sander, A., Tschope, C., Malberg, H., Bader, M., Voss, A., Altered heart rate and blood pressure variability in mice lacking the mas protooncogene. Braz. J. Med. Biol. Res. 33:1 (2000), 1–9.
178. Heringer-Walther, S., Gembardt, F., Perschel, F.H., Katz, N., Schultheiss, H.P., Walther, T., The genetic deletion of mas abolishes salt induced hypertension in mice. Eur. J. Pharmacol. 689:1–3 (2012), 147–153.
179. Lemos, V.S., Silva, D.M., Walther, T., Alenina, N., Bader, M., Santos, R.A., The endothelium-dependent vasodilator effect of the nonpeptide Ang(1–7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 46:3 (2005), 274–279.
180. Xu, P., Costa-Goncalves, A.C., Todiras, M., Rabelo, L.A., Sampaio, W.O., Moura, M.M., Santos, S.S., Luft, F.C., Bader, M., Gross, V., Alenina, N., Santos, R.A., Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 51:2 (2008), 574–580.
181. Dias-Peixoto, M.F., Santos, R.A., Gomes, E.R., Alves, M.N., Almeida, P.W., Greco, L., Rosa, M., Fauler, B., Bader, M., Alenina, N., Guatimosim, S., Molecular mechanisms involved in the angiotensin-(1–7)/mas signaling pathway in cardiomyocytes. Hypertension 52:3 (2008), 542–548.
182. Mario, E.G., Santos, S.H., Ferreira, A.V., Bader, M., Santos, R.A., Botion, L.M., Angiotensin-(1–7) mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. Peptides 33:1 (2012), 174–177.
183. Ferrario, C.M., Brosnihan, K.B., Diz, D.I., Jaiswal, N., Khosla, M.C., Milsted, A., Tallant, E.A., Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension 18:5 Suppl (1991), III126–III133.
184. Khosla, M.C., Smeby, R.R., Bumps, F.M., Structural-activity relationship in angiotensin II analogs. Angiotensin. Handbook of Experimental Pharmacology XXXVII, 1974, 126–161.
185. Santos, R.A., Ferreira, A.J., Verano-Braga, T., Bader, M., Angiotensin-converting enzyme 2, angiotensin-(1–7) and mas: new players of the renin-angiotensin system. J. Endocrinol. 216:2 (2013), R1–R17.
186. De Mello, W.C., Danser, A.H., Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 35:6 (2000), 1183–1188.
187. Xu, J., Carretero, O.A., Lin, C.X., Cavasin, M.A., Shesely, E.G., Yang, J.J., Reudelhuber, T.L., Yang, X.P., Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 293:3 (2007), H1900–H1907.
188. Crowley, S.D., Gurley, S.B., Herrera, M.J., Ruiz, P., Griffiths, R., Kumar, A.P., Kim, H.S., Smithies, O., Le, T.H., Coffman, T.M., Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl. Acad. Sci. U. S. A. 103:47 (2006), 17985–17990.
189. Reudelhuber, T.L., Bernstein, K.E., Delafontaine, P., Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension 49:6 (2007), 1196–1201.
190. Navar, L.G., Inscho, E.W., Majid, S.A., Imig, J.D., Harrison-Bernard, L.M., Mitchell, K.D., Paracrine regulation of the renal microcirculation. Physiol. Rev. 76:2 (1996), 425–536.
191. Zhuo, J.L., Li, X.C., Proximal nephron. Comp. Physiol. 3:3 (2013), 1079–1123.
192. Jancovski, N., Bassi, J.K., Carter, D.A., Choong, Y.T., Connelly, A., Nguyen, T.P., Chen, D., Lukoshkova, E.V., Menuet, C., Head, G.A., Allen, A.M., Stimulation of angiotensin type 1A receptors on catecholaminergic cells contributes to angiotensin-dependent hypertension. Hypertension 62:5 (2013), 866–871.
193. Young, C.N., Davisson, R.L., Angiotensin-II, the brain, and hypertension: an update. Hypertension 66:5 (2015), 920–926.
194. Romero, D.G., Gomez-Sanchez, E.P., Gomez-Sanchez, C.E., Angiotensin II-regulated transcription regulatory genes in adrenal steroidogenesis. Physiol. Genomics 42A:4 (2010), 259–266.
195. Bassett, M.H., White, P.C., Rainey, W.E., The regulation of aldosterone synthase expression. Mol. Cell. Endocrinol. 217:1–2 (2004), 67–74.
196. Ferrario, C.M., Chappell, M.C., Tallant, E.A., Brosnihan, K.B., Diz, D.I., Counterregulatory actions of angiotensin-(1–7). Hypertension 30:3 Pt. 2 (1997), 535–541.
197. Campbell, D.J., Kladis, A., Duncan, A.M., Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 22:4 (1993), 513–522.
198. Yamazato, M., Yamazato, Y., Sun, C., Diez-Freire, C., Raizada, M.K., Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49:4 (2007), 926–931.
199. Diez-Freire, C., Vazquez, J., Correa de Adjounian, M.F., Ferrari, M.F., Yuan, L., Silver, X., Torres, R., Raizada, M.K., ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics 27:1 (2006), 12–19.
200. Liu, C.X., Hu, Q., Wang, Y., Zhang, W., Ma, Z.Y., Feng, J.B., Wang, R., Wang, X.P., Dong, B., Gao, F., Zhang, M.X., Zhang, Y., Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol. Med. 17:1–2 (2011), 59–69.
201. Santos, R.A., Ferreira, A.J., Nadu, A.P., Braga, A.N., de Almeida, A.P., Campagnole-Santos, M.J., Baltatu, O., Iliescu, R., Reudelhuber, T.L., Bader, M., Expression of an angiotensin-(1–7)-producing fusion protein produces cardioprotective effects in rats. Physiol. Genomics 17:3 (2004), 292–299.
202. Botelho-Santos, G.A., Sampaio, W.O., Reudelhuber, T.L., Bader, M., Campagnole-Santos, M.J., Souza dos Santos, R.A., Expression of an angiotensin-(1–7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am. J. Physiol. Heart Circ. Physiol. 292:5 (2007), H2485–H2490.
203. Ferreira, A.J., Pinheiro, S.V., Castro, C.H., Silva, G.A., Silva, A.C., Almeida, A.P., Bader, M., Rentzsch, B., Reudelhuber, T.L., Santos, R.A., Renal function in transgenic rats expressing an angiotensin-(1–7)-producing fusion protein. Regul. Pept. 137:3 (2006), 128–133.
204. Rentzsch, B., Todiras, M., Iliescu, R., Popova, E., Campos, L.A., Oliveira, M.L., Baltatu, O.C., Santos, R.A., Bader, M., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52:5 (2008), 967–973.
205. Breitling, S., Krauszman, A., Parihar, R., Walther, T., Friedberg, M.K., Kuebler, W.M., Dose-dependent, therapeutic potential of angiotensin-(1–7) for the treatment of pulmonary arterial hypertension. Pulm. Circ. 5:4 (2015), 649–657.
206. Zhang, T., Li, Z., Dang, H., Chen, R., Liaw, C., Tran, T.A., Boatman, P.D., Connolly, D.T., Adams, J.W., Inhibition of mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 302:1 (2012), H299–H311.
207. Wiemer, G., Dobrucki, L.W., Louka, F.R., Malinski, T., Heitsch, H., AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium. Hypertension 40:6 (2002), 847–852.
208. Pinheiro, S.V., Simoes e Silva, A.C., Sampaio, W.O., de Paula, R.D., Mendes, E.P., Bontempo, E.D., Pesquero, J.B., Walther, T., Alenina, N., Bader, M., Bleich, M., Santos, R.A., Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor mas agonist in the mouse kidney. Hypertension 44:4 (2004), 490–496.
209. Faria-Silva, R., Duarte, F.V., Santos, R.A., Short-term angiotensin(1–7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 46:4 (2005), 948–952.
210. Ferreira, A.J., Jacoby, B.A., Araujo, C.A., Macedo, F.A., Silva, G.A., Almeida, A.P., Caliari, M.V., Santos, R.A., The nonpeptide angiotensin-(1–7) receptor mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 292:2 (2007), H1113–H1119.
211. Benter, I.F., Yousif, M.H., Cojocel, C., Al-Maghrebi, M., Diz, D.I., Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292:1 (2007), H666–H672.
212. Toton-Zuranska, J., Gajda, M., Pyka-Fosciak, G., Kus, K., Pawlowska, M., Niepsuj, A., Wolkow, P., Olszanecki, R., Jawien, J., Korbu, R., AVE 0991-angiotensin-(1–7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J. Physiol. Pharmacol. 61:2 (2010), 181–183.
213. Skiba, D.S., Nosalski, R., Mikolajczyk, T.P., Siedlinski, M., Rios, F.J., Montezano, A.C., Jawien, J., Olszanecki, R., Korbut, R., Czesnikiewicz-Guzik, M., Touyz, R.M., Guzik, T.J., Antiatherosclerotic effect of Ang-(1–7) non-peptide mimetic (AVE 0991) is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br. J. Pharmacol., 2016, 10.1111/bph.13685.
214. da Silveira, K.D., Coelho, F.M., Vieira, A.T., Sachs, D., Barroso, L.C., Costa, V.V., Bretas, T.L., Bader, M., de Sousa, L.P., da Silva, T.A., dos Santos, R.A., Simoes e Silva, A.C., Teixeira, M.M., Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J. Immunol. 185:9 (2010), 5569–5576.
215. Ma, Y., Huang, H., Jiang, J., Wu, L., Lin, C., Tang, A., Dai, G., He, J., Chen, Y., AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress. Biochem. Biophys. Res. Commun. 474:4 (2016), 621–625.
216. Fukasawa, K., Fukasawa, K.M., Kanai, M., Fujii, S., Hirose, J., Harada, M., Dipeptidyl peptidase III is a zinc metallo-exopeptidase. Molecular cloning and expression. Biochem. J. 329:Pt. 2 (1998), 275–282.
217. Shimamori, Y., Watanabe, Y., Fujimoto, Y., Purification and characterization of dipeptidyl aminopeptidase III from human placenta. Chem. Pharm. Bull. (Tokyo) 34:8 (1986), 3333–3340.
218. Ohkubo, I., Li, Y.H., Maeda, T., Yamamoto, Y., Yamane, T., Du, P.G., Nishi, K., Dipeptidyl peptidase III from rat liver cytosol: purification, molecular cloning and immunohistochemical localization. Biol. Chem. 380:12 (1999), 1421–1430.
219. Ocaranza, M.P., Jalil, J.E., On endogenous angiotensin II antagonism in hypertension: the role of dipeptidyl peptidase III. Hypertension 68:3 (2016), 552–554.
220. Cruz-Diaz, N., Wilson, B.A., Pirro, N.T., Brosnihan, K.B., Marshall, A.C., Chappell, M.C., Identification of dipeptidyl peptidase 3 as the angiotensin-(1–7) degrading peptidase in human HK-2 renal epithelial cells. Peptides 83 (2016), 29–37.
221. Dell'Italia, L.J., Ferrario, C.M., The never-ending story of angiotensin peptides: beyond angiotensin I and II. Circ. Res. 112:8 (2013), 1086–1087.
222. Jankowski, V., Vanholder, R., van der Giet, M., Tolle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Tran, T.N., Tepel, M., Schuchardt, M., Schluter, H., Wiedon, A., Beyermann, M., Bader, M., Todiras, M., Zidek, W., Jankowski, J., Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler. Thromb. Vasc. Biol. 27:2 (2007), 297–302.
223. Soltani, H.A., Javanmardi, K., Kouhpayeh, A., Baharamali, E., Farjam, M., Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats. Circ. J. 81:3 (2017), 405–412.
224. 2R) and receptor mas: a complex liaison. Clin. Sci. (Lond.) 128:4 (2015), 227–234.
225. Campbell, D.J., Clinical relevance of local renin angiotensin systems. Front. Endocrinol. (Lausanne), 5, 2014, 113, 10.3389/fendo.2014.00113.